Organogenesis (NASDAQ:ORGO – Get Free Report) will release its earnings data after the market closes on Tuesday, November ...

Medicare reimbursement issues expected for certain of Organogenesis' skin substitute projects disrupting revenues in 2025. Major catalyst is expected for ORGO with BLA filing in late 2025.

Organogenesis is a regenerative medicine company with an advanced wound care niche, and it's looking to take over a ...

Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes solutions for advanced wound care and surgical and sports medicine markets ...

"They are expanding their production facility to produce a line of artificial skin,” said Jeff Miller, EVP of investments and ...

The Rhode Island Commerce Corporation is scheduled to meet on Thursday morning to consider millions of dollars in incentives ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Organogenesis is the process by which the internal organs and specific structures such as the limb are formed during development of an organism. Organogenesis involves the coordination of multiple ...

But really bad investments should be rare. So take a moment to sympathize with the long term shareholders of Organogenesis Holdings Inc. (NASDAQ:ORGO), who have seen the share price tank a massive 73% ...

先天畸形的发生与妊娠早期的环境因素密切相关，尤其是在器官发生（organogenesis）期间。热暴露可能导致蛋白质合成障碍和DNA损伤，从而增加胎儿器官发育的异常风险。例如，神经管畸形（neural ...

Bioventus (BVS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for ...

As the U.S. stock market navigates the uncertainty surrounding the presidential election and upcoming Federal Reserve interest rate decisions, investors are keeping a close eye on various sectors for ...